RNA

Avidity Biosciences Inc

Add to Watchlist

Advanced Chart

28.970

+0.570(+2.010%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

29.090

Open

28.350

VWAP

28.54

Vol

975.69K

Mkt Cap

3.49B

Low

27.6501

Amount

27.85M

EV/EBITDA(TTM)

Total Shares

107.77M

2.04B

EV/OCF(TTM)

P/S(TTM)

388.25

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

2.87M

-3.59%

-1.407

+75.83%

2.86M

+22.64%

-1.266

+94.77%

2.87M

+40.31%

-1.132

+74.15%

Estimates Revision

The market is revising Upward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by 4.32% over the past three months. During the same period, the stock price has changed by -9.47%.

Revenue Estimates for FY2025

Revise Upward

+4.32%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.4%

In Past 3 Month

Stock Price

Go Down

-9.47%

In Past 3 Month

12 Analyst Rating

134.14% Upside

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 67.83 USD with a low forecast of 48.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

134.14% Upside

Current: 28.970

Low

48.00

Averages

67.83

High

96.00

134.14% Upside

Current: 28.970

Low

48.00

Averages

67.83

High

96.00

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$65

2025-05-09

Reason

Chardan Capital

Keay Nakae

Price Target

$65

2025-05-09

Maintains

Strong Buy

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$60

2025-04-09

Reason

Needham

Joseph Stringer

Price Target

$60

2025-04-09

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$72

2025-03-18

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$72

2025-03-18

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$65

2025-03-17

Reason

Chardan Capital

Keay Nakae

Price Target

$65

2025-03-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$72

2025-03-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$72

2025-03-17

Reiterates

Strong Buy

Reason

Needham

Joseph Stringer

Strong Buy

Reiterates

$60

2025-03-17

Reason

Needham

Joseph Stringer

Price Target

$60

2025-03-17

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -6.73, compared to its 5-year average forward P/E of -8.04. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.04

Current PE

-6.73

Overvalued PE

-3.49

Undervalued PE

-12.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.99

Current EV/EBITDA

-4.16

Overvalued EV/EBITDA

-0.86

Undervalued EV/EBITDA

-9.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

206.77

Current PS

548.16

Overvalued PS

381.51

Undervalued PS

32.04

Financials

Annual

Quarterly

FY2025Q1

YoY :

-55.60%

1.57M

Total Revenue

FY2025Q1

YoY :

+70.39%

-131.52M

Operating Profit

FY2025Q1

YoY :

+68.14%

-115.77M

Net Income after Tax

FY2025Q1

YoY :

+13.92%

-0.90

EPS - Diluted

FY2025Q1

YoY :

+80.35%

-128.58M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+209.26%

-4.09K

FCF Margin - %

FY2025Q1

YoY :

+278.72%

-7.36K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.3M

USD

3-6

Months

5.2M

USD

6-9

Months

21.1M

USD

0-12

Months

24.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

456.5K

Volume

6-9

Months

524.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.4M

Volume

Months

6-9

0.0

Volume

Months

0-12

7.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.3M

USD

3-6

Months

5.2M

USD

6-9

Months

21.1M

USD

0-12

Months

24.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RNA News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

16:10:38

Avidity Biosciences reports Q1 EPS (90c), consensus (88c)

2025-05-06 (ET)

2025-05-06

13:07:28

Controversial doctor Vinay Prasad named CBER director, STAT reports

2025-04-21 (ET)

2025-04-21

12:17:11

RBC sees Makary interview as potentially positive for biotech stocks

News

9.5

05-08PRnewswire

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

4.0

05-07Benzinga

Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target

1.0

05-06PRnewswire

Avidity Biosciences to Participate in Upcoming Investor Conference

People Also Watch

Envista Holdings Corp

First Interstate Bancsystem Inc

Excelerate Energy Inc

Artisan Partners Asset Management Inc

Cathay General Bancorp

44.430

USD

+0.25%

FAQ

What is Avidity Biosciences Inc (RNA) stock price today?

The current price of RNA is 28.97 USD — it has increased 2.01 % in the last trading day.

RNA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

RNA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Avidity Biosciences Inc (RNA) stock price today?

What is Avidity Biosciences Inc (RNA)'s business?

What is the price predicton of RNA Stock?

What is Avidity Biosciences Inc (RNA)'s revenue for the last quarter?

What is Avidity Biosciences Inc (RNA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Avidity Biosciences Inc (RNA)'s fundamentals?

How many employees does Avidity Biosciences Inc (RNA). have?

What is Avidity Biosciences Inc (RNA) market cap?